Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06224192 · ClinicalTrials.gov registry record · Phase 3
A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis
A Phase 3 study of Atopic Dermatitis, sponsored by Amgen.
- Active
- Registry status
- Phase 3
- Development phase
- 151
- Enrollment target
- 20
- Study locations
NCT06224192 is a Phase 3 study of Atopic Dermatitis that is active but no longer recruiting, run by Amgen. The registered enrollment target is 151 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT06224192, a Phase 3 study of Atopic Dermatitis, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 151 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to assess successful self-administration of rocatinlimab subcutaneously using devices for injection.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Rocatinlimab Prefilled Syringe
- COMBINATION_PRODUCT Rocatinlimab AI
Study Locations (20)
California
- Kern Research Inc - Bakersfield
- Long Beach Research Institute - Long Beach
- Dermatology Research Associates - Los Angeles
- Havana Research Institute Inc - Pasadena
- Integrative Skin Science and Research - Sacramento
Nevada
- Excel Clinical Research - Las Vegas
- Las Vegas Clinical Trials - North Las Vegas
- Skin Cancer and Dermatology Institute - Reno
Florida
- Direct Helpers Research Center - Hialeah
- Anchor Medical Research - Miami
Ohio
- Bexley Dermatology Research - Bexley
- Apex Clinical Research Center LLC - Mayfield Heights
Georgia
- Hamilton Research, LLC - Alpharetta
Idaho
- Treasure Valley Medical Research - Boise
Kansas
- Dermatology and Skin Cancer Center Leawood - Leawood
North Carolina
- The Skin Surgery Center for Clinical Research - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2024-04-02 |
| Est. Completion | 2026-03-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06224192
The ClinicalTrials.gov registry entry for NCT06224192 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (75% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Rocatinlimab Prefilled Syringe is the first listed.
NCT06224192 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Nevada, Florida.
Frequently Asked Questions
What is clinical trial NCT06224192 about?
NCT06224192 is a clinical study titled "A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe Atopic Dermatitis". The primary objective of this study is to assess successful self-administration of rocatinlimab subcutaneously using devices for injection.
What is the current status of trial NCT06224192?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 151 participants. The study started on 2024-04-02. Estimated completion is 2026-03-16.
What conditions does trial NCT06224192 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT06224192?
The interventions under investigation include: Rocatinlimab Prefilled Syringe (COMBINATION_PRODUCT), Rocatinlimab AI (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06224192?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06224192 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Idaho, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
RECRUITING · Phase 3
-
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
RECRUITING · Phase 3
-
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
RECRUITING · Phase 3
-
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.